Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
1. Grail shares surged 20% to lead Nasdaq 100 gainers. 2. Fiscal 2025 sales of Galleri blood test expected to rise 20% to 30%. 3. Grail has $767 million cash on hand to sustain operations into 2028. 4. Company projects fiscal 2024 revenue of $124 million to $126 million. 5. Shares were stable until a significant jump on Wednesday.